Obada Abou-Assali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Obada Abou-Assali has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Mengmeng Chang
Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL, United States
3 shared publicationsMichelle Reiser
Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL, United States
3 shared publications- Sami F. Noujaim
Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL, United States
3 shared publications Bojjibabu Chidipi
Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL, United States
2 shared publicationsCharles Szekeres
Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, United States
2 shared publicationsLaurent Calcul
Department of Chemistry, College of Arts and Sciences, University of South Florida, Tampa, FL, United States
2 shared publications
Latest Publications
- Open Access
- 8 September 2025
- Published by Elsevier in Heart Rhythm
- Vol. 23 (3) , 751-765
Oxidative stress mediates cardiac electrophysiological injury in inhalation exposure to flavored vaping products
- 8 September 2025
- Published by Elsevier in Heart Rhythm
- Vol. 23 (3) , 751-765
Open AccessOxidative stress mediates cardiac electrophysiological injury in inhalation exposure to flavored vaping products
- Open Access
Oxidative stress mediates cardiac electrophysiological injury in inhalation exposure to flavored vaping products
Background Electronic nicotine delivery systems (ENDS) heat “E-liquids” to generate “E-vapor”, an aerosolized mixture containing nicotine and flavors. Flavored ENDS are popular among teens who vape, however, the possible cardiac electrophysiological harm of inhalation exposure to flavored ENDS are not fully understood. Objective To test if inhalation exposure to flavoring carbonyls in E-liquids compromises mitochondrial integrity, increases oxidative stress, and leads to cardiac electrophysiological toxicity. Methods Gas chromatography mass spectrometry (GC/MS), flow cytometry, oxygen consumption rate (OCR) measurement, in-vivo programmed electrical stimulation (PES), and multielectrode array (MEA) were used in atrial like HL-1 myocytes, hiPSC derived cardiomyocytes, and mice overexpressing mitochondrial catalase (mCAT). Results We compared the toxicity of E-vapor exposure from 30 differently flavored E-liquids in HL-1 cells using apoptotic annexin V flow cytometry. Most E-liquids were toxic. We identified the major flavoring carbonyls in these E-liquids and quantified their concentrations using GC/MS. Linear regression analysis showed that toxicity correlated with carbonyls concentration. Using flow cytometry of CellROX and TMRE staining, HL-1 cells exposed to flavored E-vapor showed increased reactive oxygen species and depolarized mitochondrial membrane potential. Additionally, exposure decreased OCR in these cells. In-vivo inhalation exposure to flavored E-vapor increased the inducible ventricular tachycardia duration in WT but not in mCAT mice compared to controls. MEA recordings in hiPSC derived cardiomyocytes exposed to flavored E-vapor, with or without nicotine, resulted in changes in the spontaneous beating rate. Conclusions Inhalation exposure to flavored ENDS negatively affects ventricular electrophysiology, in part via adverse mitochondrial remodeling, and increased oxidative stress.
Open AccessOxidative stress mediates cardiac electrophysiological injury in inhalation exposure to flavored vaping products
Background Electronic nicotine delivery systems (ENDS) heat “E-liquids” to generate “E-vapor”, an aerosolized mixture containing nicotine and flavors. Flavored ENDS are popular among teens who vape, however, the possible cardiac electrophysiological harm of inhalation exposure to flavored ENDS are not fully understood. Objective To test if inhalation exposure to flavoring carbonyls in E-liquids compromises mitochondrial integrity, increases oxidative stress, and leads to cardiac electrophysiological toxicity. Methods Gas chromatography mass spectrometry (GC/MS), flow cytometry, oxygen consumption rate (OCR) measurement, in-vivo programmed electrical stimulation (PES), and multielectrode array (MEA) were used in atrial like HL-1 myocytes, hiPSC derived cardiomyocytes, and mice overexpressing mitochondrial catalase (mCAT). Results We compared the toxicity of E-vapor exposure from 30 differently flavored E-liquids in HL-1 cells using apoptotic annexin V flow cytometry. Most E-liquids were toxic. We identified the major flavoring carbonyls in these E-liquids and quantified their concentrations using GC/MS. Linear regression analysis showed that toxicity correlated with carbonyls concentration. Using flow cytometry of CellROX and TMRE staining, HL-1 cells exposed to flavored E-vapor showed increased reactive oxygen species and depolarized mitochondrial membrane potential. Additionally, exposure decreased OCR in these cells. In-vivo inhalation exposure to flavored E-vapor increased the inducible ventricular tachycardia duration in WT but not in mCAT mice compared to controls. MEA recordings in hiPSC derived cardiomyocytes exposed to flavored E-vapor, with or without nicotine, resulted in changes in the spontaneous beating rate. Conclusions Inhalation exposure to flavored ENDS negatively affects ventricular electrophysiology, in part via adverse mitochondrial remodeling, and increased oxidative stress.
- Open Access
- 7 December 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (50)
Bioengineered peptibodies as blockers of ion channels
We engineered and produced an ion channel blocking peptibody, that targets the acetylcholine-activated inwardly rectifying potassium current (IKACh). Peptibodies are chimeric proteins generated by fusing a biologically active peptide with the fragment crystallizable (Fc) region of the human immunoglobulin G (IgG). The IKAChblocking peptibody was engineered as a fusion between the human IgG1 Fc fragment and the IKAChinhibitor tertiapinQ (TP), a 21-amino acid synthetic peptidotoxin, originally isolated from the European honey bee venom. The peptibody was purified from the culture supernatant of human embryonic kidney (HEK) cells transfected with the peptibody construct. We tested the hypothesis that the bioengineered peptibody is bioactive and a potent blocker of IKACh. In HEK cells transfected with Kir3.1 and Kir3.4, the molecular correlates of IKACh, patch clamp showed that the peptibody was ~300-fold more potent than TP. Molecular dynamics simulations suggested that the increased potency could be due to an increased stabilization of the complex formed by peptibody-Kir3.1/3.4 channels compared to tertiapin-Kir3.1/3.4 channels. In isolated mouse myocytes, the peptibody blocked carbachol (Cch)-activated IKAChin atrial cells but did not affect the potassium inwardly rectifying background current in ventricular myocytes. In anesthetized mice, the peptibody abrogated the bradycardic effects of intraperitoneal Cch injection. Moreover, in aged mice, the peptibody reduced the inducibility of atrial fibrillation, likely via blocking constitutively active IKACh. Bioengineered anti-ion channel peptibodies can be powerful and highly potent ion channel blockers, with the potential to guide the development of modulators of ion channels or antiarrhythmic modalities.
- 7 December 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (50)
Open AccessBioengineered peptibodies as blockers of ion channels
We engineered and produced an ion channel blocking peptibody, that targets the acetylcholine-activated inwardly rectifying potassium current (IKACh). Peptibodies are chimeric proteins generated by fusing a biologically active peptide with the fragment crystallizable (Fc) region of the human immunoglobulin G (IgG). The IKAChblocking peptibody was engineered as a fusion between the human IgG1 Fc fragment and the IKAChinhibitor tertiapinQ (TP), a 21-amino acid synthetic peptidotoxin, originally isolated from the European honey bee venom. The peptibody was purified from the culture supernatant of human embryonic kidney (HEK) cells transfected with the peptibody construct. We tested the hypothesis that the bioengineered peptibody is bioactive and a potent blocker of IKACh. In HEK cells transfected with Kir3.1 and Kir3.4, the molecular correlates of IKACh, patch clamp showed that the peptibody was ~300-fold more potent than TP. Molecular dynamics simulations suggested that the increased potency could be due to an increased stabilization of the complex formed by peptibody-Kir3.1/3.4 channels compared to tertiapin-Kir3.1/3.4 channels. In isolated mouse myocytes, the peptibody blocked carbachol (Cch)-activated IKAChin atrial cells but did not affect the potassium inwardly rectifying background current in ventricular myocytes. In anesthetized mice, the peptibody abrogated the bradycardic effects of intraperitoneal Cch injection. Moreover, in aged mice, the peptibody reduced the inducibility of atrial fibrillation, likely via blocking constitutively active IKACh. Bioengineered anti-ion channel peptibodies can be powerful and highly potent ion channel blockers, with the potential to guide the development of modulators of ion channels or antiarrhythmic modalities.